Galmed Pharmaceuticals Ltd (GLMD) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $0.65
• Market Cap: $4.35M
• EPS: $-3.44
• 52-Week High: $3.50
• 52-Week Low: $0.50

Market Sentiment

Galmed Pharmaceuticals Ltd currently has a Neutral sentiment score of -0.02.

About Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd. (GLMD) is a clinical-stage biopharmaceutical company headquartered in Tel Aviv, Israel, focused on developing innovative therapies for liver diseases such as non-alcoholic steatohepatitis (NASH). The company boasts a robust pipeline backed by its proprietary drug platform, targeting substantial unmet medical needs in hepatology. Galmed's lead candidate, Aramchol, has demonstrated promising clinical results, enhancing its positioning for future growth opportunities ...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Galmed Pharmaceuticals Ltd and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does GLMD pay dividends?

Galmed Pharmaceuticals Ltd (GLMD) does not currently pay a regular dividend.

What is GLMD's market cap?

Galmed Pharmaceuticals Ltd (GLMD) has a market capitalization of $4.35M with a current stock price of $0.65.